RNAi-Based Gene Therapy Rescues Developmental and Epileptic Encephalopathy in a Genetic Mouse Model

• Published in: Molecular therapy Vol. 28; no. 7; pp. 1706 - 1716
• Main Authors: Aimiuwu, Osasumwen V., Fowler, Allison M., Sah, Megha, Teoh, Jia Jie, Kanber, Ayla, Pyne, Nettie K., Petri, Sabrina, Rosenthal-Weiss, Chana, Yang, Mu, Harper, Scott Q., Frankel, Wayne N.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 08.07.2020; American Society of Gene & Cell Therapy
• Subjects: AAV9; adeno-associated virus 9; DEE; developmental and epileptic encephalopathy; DNM1; dynamin-1; epilepsy; gene therapy; infantile spasms; Lennox-Gastaut syndrome; Original; RNA interferance; epilepsy; dynamin-1; Lennox-Gastaut syndrome; developmental and epileptic encephalopathy; DEE; gene therapy; RNA interferance; AAV9; DNM1; adeno-associated virus 9; infantile spasms
• ISSN: 1525-0016; 1525-0024
• DOI: 10.1016/j.ymthe.2020.04.007

Developmental and epileptic encephalopathy (DEE) associated with de novo variants in the gene encoding dynamin-1 (DNM1) is a severe debilitating disease with no pharmacological remedy. Like most genetic DEEs, the majority of DNM1 patients suffer from therapy-resistant seizures and comorbidities such as intellectual disability, developmental delay, and hypotonia. We tested RNAi gene therapy in the Dnm1 fitful mouse model of DEE using a Dnm1-targeted therapeutic microRNA delivered by a self-complementary adeno-associated virus vector. Untreated or control-injected fitful mice have growth delay, severe ataxia, and lethal tonic-clonic seizures by 3 weeks of age. These major impairments are mitigated following a single treatment in newborn mice, along with key underlying cellular features including gliosis, cell death, and aberrant neuronal metabolic activity typically associated with recurrent seizures. Our results underscore the potential for RNAi gene therapy to treat DNM1 disease and other genetic DEEs where treatment would require inhibition of the pathogenic gene product. [Display omitted] Toxic mutations in DNM1, a gene involved in the proper functioning of brain cells, cause developmental and epileptic encephalopathy—a severe class of epilepsy with no cure. Aimiuwu and colleagues show that a single gene therapy treatment via RNA interference eliminated the toxic allele sufficiently to curb severe lethal seizures, eliminate motor and developmental deficits, and extend survival of treated mice.